The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.
Riccardo Danielli
Consultant or Advisory Role - Philogen
Roberto Patuzzo
No relevant relationships to disclose
Anna Maria Di Giacomo
No relevant relationships to disclose
Gianfranco Gallino
No relevant relationships to disclose
Annabella Di Florio
No relevant relationships to disclose
Ornella Cutaia
No relevant relationships to disclose
Andrea Lazzeri
No relevant relationships to disclose
Carolina Fazio
No relevant relationships to disclose
Leonardo Giovannoni
Employment or Leadership Position - Philogen
Pier Adelchi Ruffini
Employment or Leadership Position - Philogen
Giuliano Elia
Employment or Leadership Position - Philochem
Dario Neri
Employment or Leadership Position - Philogen
Stock Ownership - Philogen
Mario Santinami
Consultant or Advisory Role - Philogen
Michele Maio
Consultant or Advisory Role - Philogen